ARTICLE | Company News
Mylan cardiovascular news
January 7, 2013 8:00 AM UTC
In documents filed Dec. 27, 2012, a judge in the U.S. District Court for the District of Columbia denied a preliminary injunction sought by generic drug maker Mylan.
Under an October 2012 complaint, Mylan asked the court to enjoin FDA from awarding 180-day exclusivity for a generic version of valsartan to Ranbaxy Laboratories Ltd. (NSE:RANBAXY; BSE:500359, Gurgaon, India) and directing FDA to approve Mylan's generic immediately (see BioCentury, Dec. 24, 2012). ...